Interesting article reinforcing what we already know about big pharma's impending patents cliffs across a wide range of drugs.
IMO it reinforces the RAC strategy not to rush into a deal. As times progresses, and assuming our clinical results confirm the efficancy of bisantrene, the timing for a deal may well be when BP is most desperate to replenish their revenue streams.
https://finance.yahoo.com/news/pharmaceutical-industry-finds-itself-historical-164751287.html?guccounter=1
Industry news, page-1671
-
- There are more pages in this discussion • 184 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.015(0.93%) |
Mkt cap ! $276.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.55 | $456.4K | 284.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2659 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |